Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Oedema
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Mar 2017
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Ascites; Oedema
- Focus Pharmacodynamics; Registrational
- Sponsors Otsuka Pharmaceutical
- 19 Apr 2014 New trial record